Clinical trial for Drug Resistant Epilepsy
Official title Infrared Photobiomodulation in Humans With Epilepsy
ClinicalTrials.gov ID: NCT07145489
What this study is testing
- What it's testing
- Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Drug resistant epilepsy
- Age 18 or older
- Average seizure rate of at least 2 seizures per month
- Accurate seizure diary with at least 3 months recorded
You likely can't join if
- Implanted intracranial neurostimulation device (DBS or RNS)
- Intracranial shunt
- Skin photosensitivity
- Cancer on scalp
- Taking any medication that can cause photosensitivity
The study team makes the final eligibility decision.
Where it's taking place
- Boston, Massachusetts, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Boston, Massachusetts, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.